<DOC>
	<DOCNO>NCT01827722</DOCNO>
	<brief_summary>CRVO occur vessel back eye become block . This create dangerous condition vessel weak prone leakage . This result development macular edema . Previous study show inflammatory mediator growth factor , vascular endothelial growth factor ( VEGF ) , elevate patient macular edema associate CRVO . Ozurdex® approve Food Drug Administration ( FDA ) available prescription macular edema follow CRVO branch retinal vein occlusion ( BRVO ) . It also indicate treatment non-infectious uveitis affect posterior segment eye . The approved dosage 0.7 mg. Ranibizumab ( Lucentis® ) approve Food Drug Administration ( FDA ) available prescription eye disorder , wet age-related macular degeneration ( AMD ) , macular edema follow CRVO BRVO , diabetic macular edema ( DME ) . The approved dosage wet AMD macular edema follow CRVO/BROV 0.5 mg give monthly . The approved dosage DME 0.3 mg give monthly . Dr. Gonzalez conduct investigational study safety effectiveness treat CRVO-associated Macular Edema combination 0.7 mg Ozurdex® 0.5 mg Lucentis® , give separate injection eye .</brief_summary>
	<brief_title>Ozurdex Versus Ranibizumab Versus Combination Central Retinal Vein Occlusion</brief_title>
	<detailed_description>This 52 week , single mask , 1:1:1 , randomize , phase IV , multicenter injection control clinical study 24 week treatment phase follow 24 week follow phase . Subjects randomly assign Ozurdex every 16 week , Ranibizumab monthly , combination Ozurdex every 16 week Ranibizumab . Patients assign IV Ozurdex arm receive total 2 intravitreal Ozurdex injection ( combination monthly Ranibizumab sham ) administer 16 week interval begin Day 1 end Week 16 . Patients assign IV Ranibizumab arm receive injection administer monthly interval ( combination Ozurdex sham begin Day 1 Week 16 ) . Patients assign IV Ozurdex IV Ranibizumab receive total 2 intravitreal Ozurdex injection administer Week 16 interval begin Day 1 end Week 16 initial IV Ranibizumab injection administer Day 1 , treat Ranibizumab accord reinjection parameter assess monthly Week 20 ( combination Ranibizumab sham Ranibizumab reinjection parameter meet ) . Treatment end study treatment phase Week 24 standard care arm Investigator 's discretion .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Adults great equal 18 year age foveal center involve macular edema secondary CRVO diagnose within 12 month screen visit ( CRVO define eye retinal hemorrhage biomicroscopic evidence RVO [ eg telangiectatic capillary bed ] dilate [ previously dilate ] venous system least 3 quadrant retina drain affected vein . Best correct visual acuity ( ETDRS ) letter score 73 24 inclusive ( 20/40 20/320 ) study eye Screening Day 1 Mean central subfield thickness great equal 310 µm 2 OCT measurement ( Spectralis HRA + OCT ) Screening Day 1 Willing able comply clinic visit studyrelated procedure Ability provide sign informed consent form History vitreoretinal surgery study eye anticipate within 12 month Day 1 Current bilateral manifestation CRVO Decrease VA due cause CRVO study eye Prior episode RVO study eye Afferent pupillary defect , obvious unequivocal Greater 10 letter improvement BCVA Screening Day 1 History presence exudative dry macular degeneration Panretinal scatter photocoagulation sector laser photocoagulation within 3 month prior Day 1 anticipate within 4 month Day 1 Anticipated laser photocoagulation macular edema within 4 month Day 1 History evidence examination diabetic retinopathy study eye CVA MI within 3 month prior Day 1 Prior antiVEGF treatment study fellow eye within 3 month day 1 systemic antiVEGF proVEGF treatment within 6 month prior Day 1 Ocular periocular infection include active suspected viral disease cornea conjunctiva , active epithelial herpes simple keratitis ( dendritic keratitis ) , vaccinia , varicella , mycobacterial infection , fungal disease Glaucoma current ocular hypertension require 1 medication control IOP study eye history steroid induce IOP increase either eye Prior Ozurdex treatment study eye within 4 month prior Day 1 Aphakic eye rupture posterior lens capsule Anterior chamber IOL rupture posterior lens capsule Hypersensitivity component Ozurdex Ranibizumab either eye History disease , metabolic dysfunction , physical exam finding , include renal failure dialysis render patient high risk treatment complication base judgment Investigator 's his/her discretion . Sexually active men woman childbearing potential unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Macular edema</keyword>
	<keyword>Central retinal vein occlusion</keyword>
	<keyword>CRVO</keyword>
	<keyword>Retinal vein occlusion</keyword>
	<keyword>RVO</keyword>
	<keyword>Ozurdex</keyword>
	<keyword>Dexamethasone intravitreal implant</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>